Monograph on the Potential Human Reproductive and ... - OEHHA

324 CHAPIN ET AL.
Table 84
Summary of Limited Utility Developmental Toxicity Studies (Multiple Dose Levels)
Bisphenol A dose level (mg/kg bw/day)
Model (treatment) Endpoint NOAEL LOAEL BMD10 BMDL10 BMD1SD BMDL1SD Reference
Rat
Long–Evans males (gavage k Serum 17b-estradiol 0.0024 (low dose) a,b
Akingbemi et al.
PND 21–35) Experiment 1 (2004)
k Serum LH and testosterone 0.0024 (low dose) a,b
Sprague–Dawley (dietary for k pup weight at weaning (PND 70 200 General Electric,
17 weeks) 21) (1976)
Sprague–Dawley (dietary for No adverse effects reported 60 (high dose) General Electric
18 weeks) (1978)
Sprague–Dawley female pups kBody weight in lactation period 105 427 286 200 233 156 Kato et al. (2003)
(sc injection PND 0–9)
m Age of vaginal opening 26 105 345 267 159 116
k No. with normal estrous cycles 105 427 81 28
m No. with cleft clitoris 26 105 299 failed
k Ovary weight 105 427 85 59 140 93
k Uterus, wet weight 105 427 66 55 128 96
k Uterus, blotted weight 105 427 273 128 318 168
k Uterine fluid weight 26 105 42 34 139 104
m No. with polycystic ovaries r105 (lowest dose 81 24
examined)
k No. corpora lutea 105 427 238 90
k No. with corpora lutea 105 427 65 38 137 83
kCorpora lutea area r105 (lowest dose 42 37 84 66
examined)
Sprague–Dawley female pups No adverse effects reported Z97 (high dose) Kato et al. (2006)
(sc injection PND 0–9)
Sprague–Dawley (feed GD15– No adverse effects reported 3000 ppm c
Masutomi et al.
PND 10) (2004)
Mouse
CF-1 (oral by pipette, GD 11– Prostate weight and sperm Z0.020 (high dose) Ashby et al. (1999)
17) production
ICR/Jcl (s.c. GD 11–17) k Female body weight at r0.002 (low dose) a 0.065 0.017 0.088 0.021 Honma et al. (2002)
weaning
k Male body weight at birth 0.002 0.020 0.054 0.020 0.031 0.015
m Anogenital distance of females r0.002 (low
at weaning dose) a,b
mAnogenital distance of males on r0.002 (low dose) 0.035 0.020 0.035 0.020
PND 60
Birth Defects Research (Part B) 83:157–395, 2008